DBV Technologies (NASDAQ:DBVT) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday.
Several other research firms have also recently weighed in on DBVT. Zacks Investment Research upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Friday, March 30th. ValuEngine upgraded shares of DBV Technologies from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Citigroup set a $57.00 price target on shares of DBV Technologies and gave the stock a “buy” rating in a report on Wednesday, February 14th. Deutsche Bank set a $33.00 price target on shares of DBV Technologies and gave the stock a “buy” rating in a report on Tuesday, March 27th. Finally, HC Wainwright restated a “buy” rating on shares of DBV Technologies in a report on Thursday, March 15th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $46.00.
DBV Technologies stock opened at $24.79 on Wednesday. DBV Technologies has a fifty-two week low of $24.26 and a fifty-two week high of $24.38. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.37 and a current ratio of 4.37.
Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in DBV Technologies by 20.2% in the fourth quarter. Geode Capital Management LLC now owns 20,833 shares of the company’s stock worth $512,000 after acquiring an additional 3,499 shares during the period. Daiwa Securities Group Inc. bought a new stake in DBV Technologies in the fourth quarter worth about $662,000. Bailard Inc. bought a new stake in DBV Technologies in the first quarter worth about $1,084,000. Candriam Luxembourg S.C.A. bought a new stake in DBV Technologies in the fourth quarter worth about $1,230,000. Finally, OLD Mission Capital LLC raised its position in DBV Technologies by 498.5% in the fourth quarter. OLD Mission Capital LLC now owns 50,875 shares of the company’s stock worth $1,252,000 after acquiring an additional 42,374 shares during the period. 40.57% of the stock is currently owned by institutional investors and hedge funds.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.